COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00399230
Recruitment Status : Completed
First Posted : November 14, 2006
Last Update Posted : August 21, 2007
Information provided by:
Innovative Medical

Brief Summary:
To evaluate the effectiveness of NGT (Optive) vs. Systane Tears for patients with moderate to severe dry eye disease.

Condition or disease Intervention/treatment Phase
Dry Eye Drug: Optive Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • · Dry eye disease diagnosis

    • Patients must currently be using Systane tears at least once a day and for at least 1 month.
    • Normal lid position and closure
    • Male or female of legal age of consent
    • Informed consent has been obtained
    • Likely to complete all required follow-up visits

Exclusion Criteria:

  • · Concurrent enrollment in an investigational drug or device study, or participation in such a study within 30 days of entry into this study.

    • Subject has a condition, or is in a situation which, in the investigator's opinion, may put the subject at a significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00399230

Layout table for location information
United States, Virginia
Dr. Rajpal
McLean, Virginia, United States, 22102
Sponsors and Collaborators
Innovative Medical
Layout table for investigator information
Principal Investigator: Rajesh Rajpal, MD See Clearly Vision Group

Layout table for additonal information Identifier: NCT00399230    
Other Study ID Numbers: 5279
First Posted: November 14, 2006    Key Record Dates
Last Update Posted: August 21, 2007
Last Verified: August 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Conjunctival Diseases
Eye Diseases
Corneal Diseases
Lacrimal Apparatus Diseases